A randomized cardiac-procedure study found delayed platelet inhibition with fentanyl. Because all participants received midazolam, the trial did not isolate a midazolam interaction.
Patients undergoing angiography were assigned to fentanyl or no fentanyl while receiving local anesthesia and intravenous midazolam. Those requiring stents received oral ticagrelor.
The relevant subgroup showed lower ticagrelor exposure and less early platelet inhibition with fentanyl in reported analyses. Two participants assigned to no fentanyl crossed over for pain.
Midazolam was background treatment in both groups. The study therefore does not establish that midazolam caused the absorption difference or determine what would happen without it.
The trial was not powered for major clinical outcomes, and biomarker findings cannot establish a precise risk of stent thrombosis. Forensic interpretation should retain randomization, crossover, timing of oral medication, co-medication, and the difference between pharmacokinetic, platelet-function, and clinical outcomes. A combined regimen should not be reduced to a single undifferentiated sedation exposure.
Original analysis of the supplied journal article, identified as PMC6202927.